520 related articles for article (PubMed ID: 9191757)
1. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.
Doraiswamy PM; Bieber F; Kaiser L; Krishnan KR; Reuning-Scherer J; Gulanski B
Neurology; 1997 Jun; 48(6):1511-7. PubMed ID: 9191757
[TBL] [Abstract][Full Text] [Related]
2. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
3. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
[TBL] [Abstract][Full Text] [Related]
4. Memory, language, and praxis in Alzheimer's disease: norms for outpatient clinical trial populations.
Doraiswamy PM; Bieber F; Kaiser L; Connors K; Krishnan KR; Reuning-Scherer J; Gulanski B
Psychopharmacol Bull; 1997; 33(1):123-8. PubMed ID: 9133763
[TBL] [Abstract][Full Text] [Related]
5. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
[TBL] [Abstract][Full Text] [Related]
6. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.
Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T
J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978
[TBL] [Abstract][Full Text] [Related]
7. Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease.
Le Bars PL; Velasco FM; Ferguson JM; Dessain EC; Kieser M; Hoerr R
Neuropsychobiology; 2002; 45(1):19-26. PubMed ID: 11803237
[TBL] [Abstract][Full Text] [Related]
8. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
9. The reliability and validity of the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) among the elderly Chinese in Hong Kong.
Chu LW; Chiu KC; Hui SL; Yu GK; Tsui WJ; Lee PW
Ann Acad Med Singap; 2000 Jul; 29(4):474-85. PubMed ID: 11056778
[TBL] [Abstract][Full Text] [Related]
10. Validation study of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease.
Nogueira J; Freitas S; Duro D; Almeida J; Santana I
Clin Neuropsychol; 2018; 32(sup1):46-59. PubMed ID: 29566598
[TBL] [Abstract][Full Text] [Related]
11. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
12. Normative Data of Mini-Mental State Examination, Montreal Cognitive Assessment, and Alzheimer's Disease Assessment Scale-Cognitive Subscale of Community-Dwelling Older Adults in Taiwan.
Wei YC; Chen CK; Lin C; Chen PY; Hsu PC; Lin CP; Shyu YC; Huang WY
Dement Geriatr Cogn Disord; 2022; 51(4):365-376. PubMed ID: 35820405
[TBL] [Abstract][Full Text] [Related]
13. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease.
Doraiswamy PM; Kaiser L; Bieber F; Garman RL
Alzheimer Dis Assoc Disord; 2001; 15(4):174-83. PubMed ID: 11723368
[TBL] [Abstract][Full Text] [Related]
14. A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in an Icelandic elderly population.
Hannesdóttir K; Snaedal J
Nord J Psychiatry; 2002; 56(3):201-6. PubMed ID: 12079572
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease.
Gillen TE; Gregg KM; Yuan H; Kurth MC; Krishnan KR
Psychopharmacol Bull; 2001; 35(2):83-96. PubMed ID: 12397889
[TBL] [Abstract][Full Text] [Related]
16. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic value and functional correlations of the ADAS-Cog scale in Alzheimer's disease: data on NORMACODEM project].
Monllau A; Pena-Casanova J; Blesa R; Aguilar M; Bohm P; Sol JM; Hernandez G
Neurologia; 2007 Oct; 22(8):493-501. PubMed ID: 17602338
[TBL] [Abstract][Full Text] [Related]
18. Reliability and concurrent validity of Alzheimer's disease assessment scale - Cognitive subscale, Chinese version (ADAS-Cog-C) among Chinese community-dwelling older people population.
Jiang Y; Yang H; Zhao J; Wu Y; Zhou X; Cheng Z
Clin Neuropsychol; 2020 Dec; 34(sup1):43-53. PubMed ID: 32279575
[TBL] [Abstract][Full Text] [Related]
19. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts.
Cano SJ; Posner HB; Moline ML; Hurt SW; Swartz J; Hsu T; Hobart JC
J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1363-8. PubMed ID: 20881017
[TBL] [Abstract][Full Text] [Related]
20. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles.
Le Bars PL
Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S50-5. PubMed ID: 13130389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
